Rxsight’s Light Adjustable Lens Got FDA Approval

November 28, 2017 Vijay Soni 0

Rxsight’s Light Adjustable Lens Got FDA Approval By: RxSight, Inc. News ALISO VIEJO, Calif., RxSight, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved the RxSight™ Light Adjustable Lens and the Light Delivery Device (LDD) for patients with pre-existing astigmatism of ≥ 0.75 diopters undergoing cataract surgery. This [..]

FDA Approved ViiV’s Juluca® For HIV

November 28, 2017 Vijay Soni 0

FDA Approved ViiV’s Juluca® For HIV By: ViiV Healthcare News ViiV Healthcare, the global specialist HIV company, majority owned by GlaxoSmithKline, with Pfizer Inc. and Shionogi Limited as shareholders, announced that the US Food and Drug Administration (FDA) has approved Juluca®, indicated as a complete regimen for the maintenance treatment of HIV-1 [..]

Making Fuel From Emissions

November 28, 2017 Vijay Soni 0

Making Fuel From Emissions By: David L. Chandler | MIT News Office MIT researchers have developed a new system that could potentially be used for converting power plant emissions of carbon dioxide into useful fuels for cars, trucks, and planes, as well as into chemical feedstocks for a wide variety [..]

New Direction for Autoimmune Drug Design Inspired by Viral Protein

November 21, 2017 Vijay Soni 0

New Direction for Autoimmune Drug Design Inspired by Viral Protein  By: Susan Gammon | SBP Beaker Blog In the U.S. alone, 24 million people, or eight percent of the population, have autoimmune diseases such as rheumatoid arthritis, lupus, multiple sclerosis, and psoriasis. Current treatments, including the new wave of biologic [..]

FDA Approved Pfizer’s Sutent® For Renal Cell Carcinoma

November 21, 2017 Vijay Soni 0

FDA Approved Pfizer’s Sutent® For Renal Cell Carcinoma By: Pfizer News Pfizer Inc. (NYSE:PFE) announced that the U.S. Food and Drug Administration has approved a new indication expanding the use of SUTENT® (sunitinib malate) to include the adjuvant treatment of adult patients at high risk of recurrent renal cell carcinoma [..]

Collision Conference

November 20, 2017 Vijay Soni 0

Collision Conference NEW ORLEANS, April 30 – May 3, 2018                   From the organizers of Web Summit, Collision is regarded as one of the best conferences in the world for tech entrepreneurs. Many of my peers rave about every aspect of this conference: From [..]

FDA Approved Genentech’s Hemlibra for Hemophilia A

November 20, 2017 Vijay Soni 0

FDA Approved Genentech’s Hemlibra for Hemophilia A By: Genentech News Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced that the U.S. Food and Drug Administration (FDA) has approved HEMLIBRA® (emicizumab-kxwh) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and children [..]

Ultragenyx’s MEPSEVII™ Got FDA Approval

November 20, 2017 Vijay Soni 0

Ultragenyx’s MEPSEVII™ Got FDA Approval NOVATO, Calif., (GLOBE NEWSWIRE) — Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, announced that the U.S. Food and Drug Administration (FDA) has approved MEPSEVII™ (vestronidase alfa), the first medicine approved for the treatment of [..]

Novel Way to Make Nanoscale Emulsions

November 8, 2017 Vijay Soni 0

Novel Way to Make Nanoscale Emulsions By: David L. Chandler | MIT News Office  The reluctance of oil and water to mix together and stay that way is so well-known that it has become a cliché for describing any two things that do not go together well. Now, a new [..]